Lead Product(s) : Lacosamide
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The positive opinion is based, in part, on results from a phase 3 study of lacosamide as adjunctive treatment for uncontrolled primary generalized tonic-clonic seizures (PGTCS), recently published in the Journal of Neurology, Neurosurgery & Psychiatry.
Product Name : Vimpat
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 22, 2020
Lead Product(s) : Lacosamide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lacosamide
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period comp...
Product Name : Vimpat
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Lacosamide
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Padsevonil
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UCB provides an update on Phase 2b padsevonil safety and efficacy study in epilepsy (ARISE)
Details : ARISE did not reach statistical significance for either of the two primary endpoints.
Product Name : UCB0942
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2020
Lead Product(s) : Padsevonil
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable